HUTCHMED (LON:HCM) Sets New 1-Year Low - Should You Sell?

Key Points

• Shares of HUTCHMED hit a new 52-week low, trading as low as GBX 191.98 and last at GBX 193 on volume of 35,840 shares (prior close GBX 198).
• The stock is trading below its 50‑day (GBX 211.60) and 200‑day (GBX 215.37) moving averages and has a low P/E of 3.64 with a market capitalization of £1.66 billion.
• HUTCHMED is a China‑focused oncology drug developer with three approved oncology medicines in China and listings on Nasdaq, HKEX and the London AIM market.

Shares of HUTCHMED (China) Limited (LON:HCM - ) hit a new 52-week low during trading on Thursday . The stock traded as low as GBX 191.98 and last traded at GBX 193, with a volume of 35840 shares. The stock had previously closed at GBX 198.

HUTCHMED Stock Performance

The firm's fifty day moving average price is GBX 211.60 and its 200 day moving average price is GBX 215.37. The company has a current ratio of 4.96, a quick ratio of 2.97 and a debt-to-equity ratio of 7.91. The stock has a market capitalization of £1.66 billion, a price-to-earnings ratio of 3.64 and a beta of 0.45.

About HUTCHMED

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.